Pieris AG

SAN DIEGO, California, December 13, 2011 - -- Breadth of Pharmacokinetic Data Points to Tunable Half-life for Platform -- Pieris AG presented novel preclinical in vitro and in vivo data for its PRS-080 Anticalin hepcidin antagonist in an oral presentation at the American Society of Hematology Annual Meeting, the company announced today.

SAN FRANCISCO, November 15, 2011 - - Results Establish Safety, Tolerability, Lack of Immunogenicity and PK/PD Profile for First Anticalin in a Clinical Setting - Pieris AG presented the results of the Company's first clinical evaluation of its most advanced Anticalin, PRS-050, an anti-VEGF targeted protein therapeutic, at the 2011 AACR-NCI-EORTC International Conference held in San Francisco, California.

FREISING, Germany, October 19, 2011 - -- Consortium Will Receive Six Million Euro from Seventh Framework Programme -- The EUROCALIN Consortium, comprising 10 companies and universities from across Europe, has initiated a collaboration focused on attaining and completing initial clinical development of a novel Anticalin therapeutic.

FREISING, Germany, October 19, 2011 - In concert with the award of the EU FP7 Grant to the Pieris-led EUROCALIN Consortium that will enable initial clinical development of Pieris' proprietary hepcidin antagonist program, the company announced today the positive strategic impact of the grant funding on its proprietary Anticalin pipeline.

FREISING, Germany, May 23, 2011 - - Data to be Presented at BioIron Society Meeting in Vancouver Pieris AG announced today preclinical in vitro and in vivo data for its PRS-080 Anticalin antagonist program targeting hepcidin, a small peptide which plays a pivotal role in the regulation of iron levels in the blood.